Evidence map›Paper›PMID 30777131›Full record

ArticleJournal for immunotherapy of cancer2019

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.

Elizabeth I Buchbinder, Janice P Dutcher, Gregory A Daniels, Brendan D Curti, Sapna P Patel, Shernan G Holtan, Gerald P Miletello, Mayer N Fishman, Rene Gonzalez, Joseph I Clark and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 2 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 2 syntheses or guidelines pooled it, 144 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Cardiotoxicity of T cell immunotherapies.Nature reviews. Cardiology · 2026
    Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 15 institutions in 4 countries.

Elizabeth I BuchbinderDana Farber Cancer Institute, Boston, MA, USA. elizabeth_buchbinder@dfci.harvard.edu.ORCID 0000-0002-7979-8953
Janice P DutcherCancer Research Foundation of NY, Chappaqua,, NY, USA.
Gregory A DanielsMoores UCSD Cancer Center, La Jolla, San Diego, CA, USA.
Brendan D CurtiProvidence Health & Services, Portland, OR, USA.
Sapna P PatelThe University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Shernan G HoltanUniversity of Minnesota, Minneapolis, MN, USA.
Gerald P MiletelloHematology/Oncology Clinic, Baton Rouge, LA, USA.
Mayer N FishmanMoffitt Cancer Center, Tampa, FL, USA.
Rene GonzalezUniversity of Colorado, Aurora, CO, USA.
Joseph I ClarkLoyola University Stritch School of Medicine, Maywood, IL, USA.
John M RichartSaint Louis University, Saint Louis, MO, 63110, USA.
Christopher D LaoUniversity of Michigan, Ann Arbor, MI, USA.
Scott S TykodiUniversity of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Ann W SilkRutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
David F McDermottBeth Israel Deaconess Medical Center, Boston, MA, USA.
Beth Israel Deaconess Medical Center · USDana-Farber Cancer Institute · USHematology\Oncology Clinic · USKids' Brain Tumor Cure Foundation · USLoyola University Chicago · USMoffitt Cancer Center · USProvidence Health & Services · USRutgers, The State University of New Jersey · USSaint Louis University · ESThe University of Texas MD Anderson Cancer Center · USUC San Diego Health System · USUniversity of Colorado System · USUniversity of Michigan · USUniversity of Minnesota · USUniversity of Washington · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Douglas Yee · 1998 to 2026
$100.4M
NCI NIH HHS P30 CA077598
6 · The paper itself

Abstract

backgroundMetastatic melanoma (mM) and renal cell carcinoma (mRCC) are often treated with anti-PD-1 based therapy, however not all patients respond and further therapies are needed. High dose interleukin-2 (HD IL-2) can lead to durable responses in a subset of mM and mRCC patients. The efficacy and toxicity of HD IL-2 therapy following anti-PD-1 or anti-PD-L1 therapy have not yet been explored.

methodsReports on mM and mRCC patients who had received HD IL-2 after PD-1 or PD-L1 inhibition were queried from the PROCLAIM

resultsA total of 57 patients (40 mM, 17 mRCC) were treated with high dose IL-2 after PD-1 or PD-L1 inhibition and had data recorded in the PROCLAIM database. The best overall response rate to HD IL-2 was 22.5% for mM (4 complete response (CR), 5 partial responses (PRs)) and 24% for mRCC (2 CRs, 2 PRs). The toxicity related to HD IL-2 observed in these patients was similar to that observed in patients treated with HD IL-2 without prior checkpoint blockade. One patient who had received prior PD-L1 blockade developed drug induced pneumonitis with HD IL-2 requiring steroid therapy.

conclusionIn this retrospective analysis, HD IL-2 therapy displayed durable antitumor activity in mM and mRCC patients who progressed following treatment with PD-1 and PD-L1 inhibition. The toxicities were generally manageable and consistent with expectations from HD IL-2 but physicians should watch for immune related toxicities such as pneumonitis. This analysis supports the development of randomized prospective trials to assess the proper sequencing and combination of immune checkpoint blockade and cytokine therapy.

Indexed as

AdolescentAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 AntigenCarcinoma, Renal CellFemaleHumansInterleukin-2Kaplan-Meier EstimateKidney NeoplasmsMaleMelanomaMiddle AgedAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 AntigenCD274 protein, humanInterleukin-2NivolumabPDCD1 protein, humanpembrolizumabProgrammed Cell Death 1 Receptor

Identifiers

PMID30777131
PMCPMC6380045
OpenAlexW2918019324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.